Business Context and Reporting Period
This Form 8-K filing by Oscar Health, Inc. (OSCR) reports corporate governance changes effective December 7, 2022. The report was filed on December 6, 2022, pursuant to Item 5.02 regarding the appointment of certain officers and directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and director compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to ten directors.
- New Appointments: Ms. Laura Lang and Mr. Bill Gassen were appointed as independent directors.
- Committee Assignments: Ms. Lang was appointed Chair of the Compensation Committee. Mr. Gassen was appointed to the Nominating and Corporate Governance Committee.
Guidance, Outlook, and Compensation Details
The filing outlines the compensatory arrangements for the new non-employee directors, which include:
- Cash Retainers: $70,000 annually for Board service; $20,000 for Chair of the Compensation Committee; $5,000 for Nominating Committee membership.
- Equity Grants: An initial grant of Restricted Stock Units (RSUs) valued at $175,000, vesting one year from the grant date or at the next annual meeting, whichever is earlier.
- Annual Grants: Future annual RSU grants valued at $175,000, subject to the same vesting schedule.
The filing does not contain management commentary on business outlook, risks, or contingencies beyond the standard indemnification agreement expectation.
Investor Verification Checklist
- Verify the independence status of Ms. Lang and Mr. Gassen under NYSE rules.
- Confirm the impact of the expanded board on future strategic decisions and committee oversight.
- Review the total equity dilution impact of the $175,000 RSU grants per director based on the current share price.
- Check subsequent filings for the formal ratification of these appointments at the 2023 annual meeting.